ID   KBM-5
AC   CVCL_0373
SY   KBM5
DR   BTO; BTO:0002546
DR   MCCL; MCC:0000268
DR   cancercelllines; CVCL_0373
DR   ChEMBL-Cells; CHEMBL4483148
DR   ChEMBL-Targets; CHEMBL4483250
DR   IARC_TP53; 4652
DR   PubChem_Cell_line; CVCL_0373
DR   Wikidata; Q54899585
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3332852;
RX   PubMed=7627932;
RX   PubMed=8339266;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=26623729;
CC   Doubling time: 24-60 hours (PubMed=8339266).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=8339266; PubMed=10071072; PubMed=10576511).
CC   Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Gly710Ter (c.2128G>T); Zygosity=Homozygous (PubMed=26623729).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=7627932; PubMed=26623729).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 18
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=7627932; DOI=10.1016/0165-4608(94)00282-g;
RA   Sen S., Zhou H.-Y., Andersson B.S., Cork A., Freireich E.J.,
RA   Stass S.A.;
RT   "p53 gene mutations with chromosome 17 abnormalities in chronic
RT   myelogenous leukemia blast crisis patients persist in long-term cell
RT   lines but may be acquired in acute myeloid leukemia cells in vitro.";
RL   Cancer Genet. Cytogenet. 82:35-40(1995).
//
RX   PubMed=8339266;
RA   Beran M., Pisa P., O'Brien S., Kurzrock R., Siciliano M.J., Cork A.,
RA   Andersson B.S., Kohli V., Kantarjian H.M.;
RT   "Biological properties and growth in SCID mice of a new myelogenous
RT   leukemia cell line (KBM-5) derived from chronic myelogenous leukemia
RT   cells in the blastic phase.";
RL   Cancer Res. 53:3603-3610(1993).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=26623729; DOI=10.18632/oncotarget.6392; PMCID=PMC4792541;
RA   Valletta S., Dolatshad H., Bartenstein M., Yip B.H., Bello E.,
RA   Gordon S., Yu Y.-T., Shaw J., Roy S., Scifo L., Schuh A., Pellagatti A.,
RA   Fulga T.A., Verma A., Boultwood J.;
RT   "ASXL1 mutation correction by CRISPR/Cas9 restores gene function in
RT   leukemia cells and increases survival in mouse xenografts.";
RL   Oncotarget 6:44061-44071(2015).
//